Loading company financials…
Nasdaq · Biological Products, (No Diagnostic Substances) · CIK 0001682852
$145.55
+5.48% · delayed 15 min
$57.35B market value
What this company does
Moderna develops and makes medicines. It took in $1.94B last year, which makes it a mid-sized company. It spends more than it earns — losing about 145 cents on every dollar of sales.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From Moderna, Inc.'s FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
Measured against FY2024, from the 10-K
Deteriorated: -39.9%
$3.24B to $1.94B
Improved: $739.0M narrower
-$3.56B to -$2.82B
Deteriorated: −35.1 pts
-110.0% to
It holds more cash than debt, so borrowings are not a pressure.
$2.00B more cash than debt
A widely used bankruptcy-risk model places it well clear of distress.
Altman Z 9.93
It loses money, so it depends on cash reserves or new funding to keep going.
$2.82B lost last year
Sales are shrinking rather than growing.
down 39.9% on last year
It keeps less of each sale as profit than it did a year ago.
-110.0% → -145.2%
It fails most of the standard checks of financial strength.
Piotroski 3/9
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 13.4% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
The essentials
Each answered from the filings, with the numbers behind it.
No. It lost $2.82B last year, losing about 145 cents on every dollar of sales.
What it earns, what it keeps, and what it costs to run — all from the same filing
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it lost $2.82B and generated -$1.87B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Nothing recent
No insider trades, pending-sale notices or 5% stake filings from MRNA in the last few months. That is the ordinary case, not a gap.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Major event announcement(8-K) | 2026-09-01 | 2026-08-27 |
| Quarterly report(10-Q) | 2026-07-31 | 2026-06-30 |
Financial figures are from MRNA's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing.
3 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
9.93
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: $1.99B narrower
-$4.05B to -$2.06B
Deteriorated: turned positive
$0.00 to $590.0M
Improved: +34.7%
$1.93B to $2.60B
Deteriorated: +2.1%
386.0M to 394.0M
Changed: -81.7%
$1.05B to $192.0M
1 other measure barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
No. Sales shrank 39.9% last year.
No — it holds more cash than debt, with $2.00B left over after paying off every borrowing. For every $1 it owes, it owns $3.35 in assets.
It has no profits to compare a price against, because it lost money last year.
This company has not reported enough of the required figures to calculate this score.
At a glance
| Major event announcement(8-K) | 2026-07-31 | 2026-07-31 |
| Major event announcement(8-K) | 2026-07-08 | 2026-07-06 |
| Major event announcement(8-K) | 2026-05-11 | 2026-05-06 |
| Quarterly report(10-Q) | 2026-05-01 | 2026-03-31 |
| Major event announcement(8-K) | 2026-05-01 | 2026-05-01 |
| Shareholder voting information(DEF 14A) | 2026-03-16 | 2026-05-06 |
| Major event announcement(8-K) | 2026-03-05 | 2026-03-03 |
| Annual report(10-K) | 2026-02-20 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-13 | 2026-02-13 |
| Major event announcement(8-K) | 2026-02-11 | 2026-02-03 |
| Major event announcement(8-K) | 2026-01-12 | 2026-01-12 |
| Major event announcement(8-K) | 2026-01-05 | 2026-01-05 |
| Major event announcement(8-K) | 2025-11-24 | 2025-11-19 |
| Major event announcement(8-K) | 2025-11-20 | 2025-11-20 |
| Major event announcement(8-K) | 2025-11-13 | 2025-11-12 |
| Quarterly report(10-Q) | 2025-11-06 | 2025-09-30 |
| Major event announcement(8-K) | 2025-11-06 | 2025-11-06 |
| Shareholder voting information(DEF 14A) | 2025-10-15 | 2025-11-12 |
Coverage from the last 30 days
Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
Yahoo Finance ·
How Is Moderna's Stock Performance Compared to Other Healthcare Stocks
Yahoo Finance ·
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Yahoo Finance ·
If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)
Yahoo Finance ·
What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth?
Yahoo Finance ·
Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes?
Yahoo Finance ·
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?
Yahoo Finance ·
GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says
Yahoo Finance ·
Why Moderna (MRNA) Stock Is Down Today
Yahoo Finance ·
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
Yahoo Finance ·
Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 44% Stock Drop
Yahoo Finance ·
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
Yahoo Finance ·
Primary sources and further research